A successful 2017 for Boehringer Ingelheim
The research-driven pharmaceutical company Boehringer Ingelheim can look back on a very successful 2017 financial year. All businesses contributed to net sales growth.
R&D expenditure exceeded $3.6 billion, around $3.2 billion of which was in the human pharmaceuticals area alone.
In 2017, Boehringer Ingelheim generated net sales of nearly $21 billion, and the company employed an average of approximately 50,000 people worldwide.
Christoph Raab, Head of Finance and Administration at Boehringer Ingelheim META said, “In the META, we have achieved a 10% sales growth during 2017 compared to the same period last year.“
“Our top performing markets included the United Arab Emirates, Saudi Arabia and Turkey,“ Raab added.
Enrique Manzoni, Regional Managing Director – Middle East, Turkey, Africa (META) at Boehringer Ingelheim said, “Our financial and operational performance mirrors the company’s consistent commitment towards meeting the region’s unmet medical needs by delivering innovative initiatives across a number of key therapeutic areas such as type 2 diabetes and stroke.”
“In 2017, we have been able to launch 10 products in addition to registering 38 products across the region,” added Manzoni.
Major success with human pharmaceuticals globally
In the human pharmaceuticals business, Boehringer Ingelheim last year succeeded in generating net sales of more than $1 billion (70% of total net sales) with 6 medicines that focused on respiratory illnesses such as chronic obstructive pulmonary disease (COPD) and Idiopathic pulmonary fibrosis (IPF).
Net sales in animal health have more than doubled to $4.7 billion (22% of its total net sales). The beef flavoured chews for dogs and the flea and tick treatment generated the most sales.
The biopharmaceutical manufacturing business grew by 10.7% last year to $824 million and contributed 4% to total net sales.
Holistic approaches for humans and animals
A key strategic objective of Boehringer Ingelheim globally is to develop holistic approaches that benefit patients, both human and animal.
Boehringer Ingelheim recently increased the Boehringer Ingelheim Venture Fund from $121 million to $304 million, $60 million of which is intended for digital innovation alone.
Outlook for 2018
For the current financial year, Boehringer Ingelheim globally is expecting slight growth in net sales on a comparable basis.
“In 2018, the company is expecting 33 market authorizations throughout the wider META region. In addition, we are also expanding our footprint in the Sub Saharan Africa with key investments in driving access to healthcare programs to develop innovative solutions,” concluded Manzoni